Q1 26 EPS
$N/A
Q1 26 Revenue
N/A
vs S&P Since Q1 26
+61.6%
BEATING MARKET
TDOC +68.0% vs S&P +6.4%
Market Reaction
Did TDOC Beat Earnings? Q1 2026 Results
Teladoc Health closed out fiscal 2025 on a firmer footing than Wall Street had anticipated, reporting Q4 revenue of $642.27 million, a 1.09% beat against the $635.34 million consensus, as the telehealth company managed to hold its top line essentiall… Read more Teladoc Health closed out fiscal 2025 on a firmer footing than Wall Street had anticipated, reporting Q4 revenue of $642.27 million, a 1.09% beat against the $635.34 million consensus, as the telehealth company managed to hold its top line essentially flat, up just 0.3% year-over-year amid a challenging environment. The more striking beat came on the bottom line, where a loss of $0.14 per share cleared the $0.18 consensus estimate by 22.78%, reflecting a narrowing net loss of $25.14 million versus $48.41 million a year earlier. The key driver behind the relative resilience was a 5% revenue gain in Integrated Care to $409.09 million, which offset continued deterioration in BetterHelp, where revenue slid 7% to $233.18 million and paying users fell 6% to 375,000. Upgrades from multiple Wall Street banks following the results underscore cautious optimism, though the company's 2026 guidance, which projects full-year revenue of $2.47 billion to $2.59 billion and guides BetterHelp to another potential revenue decline of up to 7%, signals the recovery remains uneven.
Key Takeaways
- • Integrated Care segment revenue growth of 5% driven by U.S. Integrated Care Members reaching 101.8 million, up 9% YoY
- • International revenue surged 19% to $125.0 million
- • Other revenue increased 24% to $120.7 million
- • Adjusted EBITDA improved 12% to $83.8 million with Integrated Care adjusted EBITDA up 23%
- • Net loss improved 48% year-over-year from reduced stock-based compensation and operational improvements
TDOC Forward Guidance & Outlook
For full year 2026, Teladoc expects revenue of $2,470–$2,587 million, adjusted EBITDA of $266–$308 million, net loss per share of ($1.10)–($0.70), free cash flow of $130–$170 million, and U.S. Integrated Care Members of 97–100 million. Integrated Care revenue growth is guided at 0.4%–3.9% with adjusted EBITDA margin of 15.1%–16.1%. BetterHelp revenue is expected to decline 0.5%–7.0% with adjusted EBITDA margin of 3.0%–4.6%. For Q1 2026, the company expects revenue of $598–$620 million, adjusted EBITDA of $50–$62 million, and net loss per share of ($0.45)–($0.35). Q1 Integrated Care revenue growth is guided at (1.2%)–2.0% and BetterHelp revenue decline of (11.25%)–(7.0%).
TDOC YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
TDOC Revenue by Segment
With YoY comparisons, source: SEC Filings
TDOC Revenue by Geography
With YoY comparisons, source: SEC Filings
“We closed 2025 with a solid finish, delivering consolidated revenue and adjusted EBITDA above the midpoint of our guidance ranges for the fourth quarter. I'm encouraged by the progress we made last year against each of our strategic priorities, as we strengthened our product portfolio, advanced innovation across Integrated Care and BetterHelp, and positioned the company to build on this momentum in 2026.”
— Chuck Divita, Q1 2026 Earnings Press Release
TDOC Earnings Trends
TDOC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TDOC EPS Trend
Earnings per share: estimate vs actual
TDOC Revenue Trend
Quarterly revenue: estimate vs actual
TDOC Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | — | — | — | — |
| Q4 25 BEAT FY | $-0.22 | $-0.14 | +35.19% | $642.3M | +1.09% |
| FY Full Year | $-0.99 | $-1.14 | -14.92% | $2.53B | +0.27% |
| Q3 25 BEAT | $-0.31 | $-0.28 | +8.94% | $626.4M | +0.06% |
| Q2 25 BEAT | $-0.31 | $-0.19 | +38.71% | $631.9M | +1.46% |
| Q1 25 MISS | $-0.36 | $-0.53 | -48.04% | $629.4M | +1.64% |